No Data
After maintaining a two-month upward trend, Huahao Zhongtian Pharmaceutical-B (02563) saw a single-day maximum decline of over 40%.
If the stock price trend does not "engulf" the large bearish candlestick formed on December 30 and does not produce a significant bullish candlestick with increasing volume recently, it indicates that the downside of the stocks may not yet have reached the end in the short term, and bottom signals have not yet appeared.
Hong Kong stock fluctuation | Huahua Zhongtian Pharmaceutical-B (02563) plummeted over 37%, erasing all gains since its listing, with the Market Cap shrinking to 7.2 billion HKD.
Huahao Zhongtian Medicine-B (02563) plummeted over 37%. The stock was listed on October 31 of this year and rose 30% on the first day, after which the stock price steadily increased. As of the time of writing, it has fallen 37.18%, trading at 19.82 Hong Kong dollars, with a transaction amount of 11.9471 million Hong Kong dollars.
[IPO Monthly Report] The hot market for Hong Kong IPOs in October remains unabated. The oversubscription ratio of Karotex was 1346 times, and China Resources Beverage may become the "capital freezing king" of the year.
In September, Midea Group Co., Ltd. (00300) raised 35.7 billion yuan, becoming the largest in the Hong Kong stock market since February 2021, the largest in Asia in the first three quarters of 2024, and the second largest in the world by 2024. The Chief Executive Officer of HKEX, Bonnie Chan Yi-Ting, stated: "Recently, the HKEX welcomed the largest in Asia and the second largest in the world in terms of new stock listings this year. Refinancing activities are also very active, demonstrating the depth and attractiveness of our market. The number of new stock listing applications further consolidates Hong Kong's position as the preferred new stock fundraising center in Asia. In addition, Alibaba has converted to a dual primary listing and was subsequently included in the Stock Connect."
After boosting its stock price by 30% through the 'routine callback', what is supporting Huahao Zhongtian Pharmaceutical-B (02563) to sustain a market cap of nearly 8 billion Hong Kong dollars?
In short, the weak profit performance and the research and development department relying solely on a single core product make Huahao Zhongtian Pharmaceuticals face a certain degree of uncertainty in future performance. In addition, the poor performance of the synthetic biology track on the secondary market globally means that Huahao Zhongtian Pharmaceuticals needs to continuously optimize its own fundamentals to prove itself in the Hong Kong stock market, while enhancing its innovation and further strengthening its own hematopoietic capacity.
New stock first day | Huahao Zhongtian Medicine-B (02563) first listed on the market, opening high in the morning by 34.38%.
Huahao Zhongtian Pharmaceutical-B (02563) made its debut on the stock market. The announcement shows that the price per share is 16 Hong Kong dollars, with a total issuance of 14.588 million shares, and 200 shares per lot. The net proceeds from the offering are expected to be approximately 0.19589 billion Hong Kong dollars. As of the time of this report, it has risen by 34.38%, trading at 21.5 Hong Kong dollars, with a turnover of 22.4505 million Hong Kong dollars.
Huahao Zhongtian Pharmaceutical-B (02563) is priced at a maximum of 21.45 times the public offering subscription.
Huahao Zhongtian Pharmaceutical-B (02563) announced the results of the distribution. The company plans to globally issue 14.588 million shares of stock, public...
